EL7.AI
StocksMedium•2 November 2026•
3 min read

Granules India profit rises to 1.82 billion rupees as revenue grows 20.3%

Key Facts

1Consolidated net profit rose to 1.82 billion rupees, from 1.31 billion rupees a year earlier.
2Operating revenue increased 20.3% to 15.60 billion rupees, with North America accounting for 72% of the total.
3Total expenses rose 18.5%, while the cost of materials consumed increased 23.2%.
4The company produces about one-third of the world's paracetamol and serves more than 80 countries through 10 manufacturing facilities.

Granules India reported consolidated net profit of 1.82 billion rupees for the quarter ended September 30, 2026, compared with 1.31 billion rupees in the year-earlier period, according to a Reuters report published on November 2. The increase came alongside 20.3% growth in operating revenue to 15.60 billion rupees. Reuters said new product launches and strong sales of key medicines in overseas markets offset higher production costs. The results highlight how sales growth supported quarterly earnings despite a marked rise in costs. North America accounted for the largest share of revenue, representing 72% of the total.

Operating revenue reached 15.60 billion rupees, up 20.3% year on year, driven by strong demand in North America, Reuters reported. The region accounted for 72% of total revenue, making its performance a key factor in the company's results. The agency said sales of key medicines in overseas markets helped support earnings. It also attributed part of the performance growth to new product launches. These factors combine an expansion in current sales with additions to the company's portfolio, as costs continue to weigh on the business.

Revenue growth came with pressure on expenses: total expenses rose 18.5% year on year in the second quarter, while the cost of materials consumed increased 23.2%, Reuters reported. Materials costs grew faster than total expenses, while revenue growth stood at 20.3%. Chairman and managing director Prasad Chigurupati said, "Cost pressures will continue, and we are working with customers to manage them as the pass-through is delayed." His remarks indicate that rising costs are being managed in coordination with customers, but their impact is not passed through immediately. As a result, some of the benefit from sales growth depends on how these pressures are managed and how long the pass-through remains delayed.

Granules operates internationally in the manufacture of paracetamol and medicines, producing about one-third of the quantity used globally and serving more than 80 countries, Reuters reported. The company operates 10 manufacturing facilities, including seven in India, two in the United States and one in Europe. This footprint places the company at the center of pharmaceutical supply chains across multiple markets, with a direct manufacturing presence in North America, the quarter's largest revenue contributor. Its base of facilities and markets also provides context for the overseas sales growth that supported results. New product launches remain one of the performance drivers cited by the agency, alongside sales of key medicines.

Factors investors are watching include U.S. approvals and new product launches, according to the Reuters report. The agency links the importance of these developments to support for newer product lines, given the significant reliance on the U.S. market for revenue. This follows a quarter in which the company combined growth in profit and revenue with increases in materials costs and expenses. Chigurupati said cost pressures would continue and that the company was working with customers to manage them as the pass-through was delayed. Approvals and new launches, along with cost management, will remain among the factors tied to the company's performance in coming periods.